重组人干扰素α2b治疗35例手足口病患儿疗效观察

Therapeutic Effect of Recombinant Human Interferon α2b on 35 Children with Hand,Foot and Mouth Disease

目的:探究重组人干扰素α2b治疗手足口病患儿疗效。方法:选取某院2017年8月~2018年9月手足口病患儿70例,随机数字表法分为对照组与观察组各35例。对照组给予利巴韦林治疗,观察组给予重组人干扰素α2b治疗,对比两组疗效及T细胞亚群水平(CD3^+、CD4^+、CD8^+、CD4^+/CD8^+)。结果:与对照组68.57%相比,观察组总有效率91.43%明显提高(P<0.05);治疗后观察组CD8^+低于对照组,CD4^+、CD3^+、CD4^+/CD8^+高于对照组(P<0.05)。结论:重组人干扰素α2b治疗手足口病患儿,可改善免疫功能,疗效显著。

Objective:To explore the efficacy of recombinant human interferonα2b in the treatment of children with hand,foot and mouth disease.Methods:70 patients with hand,foot and mouth disease in a hospital from August 2017 to September 2018 were enrolled.The random number table method was used to divide them into control group(n=35)and observation group(n=35).The control group was treated with ribavirin,and the observation group was given recombinant human interferonα2b.The efficacy and T cell subset levels(CD3^+,CD4^+,CD8^+,CD4^+/CD8^+)were compared between the two groups.Results:Compared with the control group of 68.57%,the total effective rate of the observation group was significantly increased by 91.43%(P<0.05).After treatment,the CD8^+of the observation group was lower than that of the control group,CD4^+,CD3^+,CD4^+/CD8^+was higher than the control group(P<0.05).Conclusion:Recombinant human interferonα2b can improve immune function in children with hand,foot and mouth disease,and its curative effect is remarkable.